Cancer Will No Longer Be a Financial Death Blow to Many Patients

Article

For oncologists, the impact of the Supreme Court's decision on the Affordable Care Act will likely mean that their patients will no longer be in danger of losing insurance or being denied insurance because of cancer.

James B. Yu, MD

For oncologists, the impact of the Supreme Court's decision on the Affordable Care Act will likely mean that their patients will no longer be in danger of losing insurance or being denied insurance because of cancer. The number of uninsured patients will be reduced dramatically.

I am hopeful that this will mean that cancer will no longer be a financial death blow to many patients, and that patients will not have to choose between paying the mortgage and paying for increasingly expensive chemotherapies and radiation treatments. As someone who researches comparative and cost effectiveness, I think any reexamination of cost-benefit for patients and emphasis on evidence-based practice is welcome.

More on the Supreme Court Decision

Derek Raghavan
Bruce Minsky
Nora Janjan
Michael Glod
James B. Yu
Lawrence Wagman
Recent Videos
7 experts are featured in this series.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Related Content